Abstract
HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormone) derived from mammalian cells (Serostim) is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting. Somatropin 0.1 mg/kg/day administered subcutaneously for 12 weeks effectively increased work output, bodyweight and lean body mass and improved health-related quality of life (HR-QOL), compared with placebo, and had a generally manageable tolerability profile in a large randomised study in patients with HIV-associated wasting. Potential areas for further research include determination of longer-term efficacy and tolerability, the cost effectiveness of treatment, the optimal somatropin dosage, management of patients after 12 weeks' therapy and whether maintenance strategies might exist to maintain accrued lean body mass with lower doses of somatropin. Nevertheless, indications to date are that somatropin is likely to have an important role...Continue Reading
References
Sep 15, 1994·Annals of Internal Medicine·J H Von RoennS A Weitzman
Sep 15, 1994·Annals of Internal Medicine·M H OsterN M Flynn
Dec 1, 1996·Annals of Internal Medicine·M SchambelanJ B Breitmeyer
Dec 16, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·T N Kakuda
Feb 19, 1998·The Journal of Clinical Endocrinology and Metabolism·P V CarrollM Thorne
Jun 19, 1998·AIDS·B Y NguyenR Yarchoan
Jul 4, 1998·Annals of Internal Medicine·S GrinspoonA Klibanski
Apr 20, 1999·JAMA : the Journal of the American Medical Association·A StrawfordM K Hellerstein
Jul 23, 1999·AIDS·N I PatonG E Griffin
Feb 22, 2000·JAMA : the Journal of the American Medical Association·S BhasinG Beall
Apr 13, 2000·Mayo Clinic Proceedings·P M NemechekM S Gottlieb
Aug 2, 2000·The American Journal of Clinical Nutrition·A SchwenkM Elia
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A WankeS L Gorbach
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P RietschelS Grinspoon
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·S Grinspoon, M Gelato
Aug 28, 2001·AIDS Patient Care and STDs·B PolskyC Steinhart
Oct 24, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alice M TangSherwood L Gorbach
Mar 21, 2003·AIDS·Ulrich R HenggeGary Ringham
Apr 13, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Donald P KotlerUNKNOWN Serostim in Adipose Redistribution Syndrome Study Group
Apr 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Graeme J MoyleUNKNOWN Serono 9037 Study Team
Mar 16, 2005·Archives of Internal Medicine·Kathleen MulliganUNKNOWN National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group
Aug 27, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alice M TangChristine Wanke